Sarepta's DMD Gene Therapy: Durable Responses After Two Years

After A Single Infusion

Durable responses have continued to be seen two years after administration of Sarepta’s candidate gene therapy to four boys with Duchenne muscular dystrophy.    

DNA

More from Clinical Trials

More from R&D